• Evidence of transient sensory symptoms in recipients of BNT162b2 mRNA COVID-19 is scarce. • Sensory symptom frequency in first dose recipients of BNT162b2 who reported an AEFI is 3.4% (95% CI 3.1% to 3.8%). • Arms and face/neck are the most commonly affected sites (61% and 36.2%, respectively). • Healthcare workers have lower odds for reporting sensory symptoms (aOR 0.54; 95% CI 0.40–0.72; p < 0.001). • Emphasizing vaccine efficacy and safety before vaccination may reduce immunization stress-related response. mRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI). We found an overall frequency of 3.4% (377 cases) or 4.8 cases per 100,000 doses administered. Anatomically, the arms (61%) and face/neck region (36.2%) were the most commonly affected sites. The control group had significantly higher rates of reactogenicity-associated symptoms, suggesting that NSSS are reactogenicity-independent; in multivariable analysis, healthcare workers reported sensory symptoms less frequently (aOR 0.54; 95% CI 0.40–0.72; p < 0.001). This is the first study describing the topography and associated factors for developing NSSS among BNT162b2 recipients. The benign nature of these symptoms may help dissipate hesitation towards this vaccine. [ABSTRACT FROM AUTHOR]